News
WGSWW
0.0092
+43.75%
0.0028
Casdin Capital acquires 500,000 GeneDx shares valued at $21,367,516.50
PUBT · 17h ago
Weekly Report: what happened at WGSWW last week (0511-0515)?
Weekly Report · 3d ago
GeneDx director Keith Meister reports $13.75 million Class A common share purchase
PUBT · 5d ago
GeneDx: Disappointing Q1 Creates Another Turnaround Opportunity
Seeking Alpha · 05/14 11:31
Corvex’s Keith Meister buys $48.44 million GeneDx common shares
PUBT · 05/12 01:22
Weekly Report: what happened at WGSWW last week (0504-0508)?
Weekly Report · 05/11 09:54
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Seeking Alpha · 05/08 17:25
BRIEF-Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Reuters · 05/08 10:24
ALPHABET DISSOLVES SHARE STAKE IN REPLIGEN - SEC FILING
Reuters · 05/08 10:03
GENEDX HOLDINGS CORP <WGS.O>: PIPER SANDLER CUTS TARGET PRICE TO $50 FROM $130
Reuters · 05/07 12:00
U.S. RESEARCH ROUNDUP-ARM Holdings, CDW, Doordash
Reuters · 05/07 07:37
GENEDX HOLDINGS CORP <WGS.O>: BTIG CUTS TARGET PRICE TO $90 FROM $170
Reuters · 05/05 10:18
U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi
Reuters · 05/05 07:07
GENEDX HOLDINGS CORP <WGS.O>: CANACCORD GENUITY CUTS TARGET PRICE TO $75 FROM $100
Reuters · 05/05 06:44
GENEDX HOLDINGS CORP <WGS.O>: JEFFERIES CUTS TARGET PRICE TO $100 FROM $150
Reuters · 05/05 04:49
GENEDX HOLDINGS CORP <WGS.O>: GUGGENHEIM CUTS TARGET PRICE TO $70 FROM $100
Reuters · 05/05 02:51
GeneDx expects $475M-$490M 2026 revenue as it targets at least 30% exome/genome volume growth
Seeking Alpha · 05/05 00:14
BUZZ-GeneDx plunges after trimming annual revenue forecast 
Reuters · 05/04 20:46
GeneDx Q1 revenue misses estimates, cuts FY26 outlook
Reuters · 05/04 20:19
BRIEF-GeneDx Q1 Revenue USD 102.3 Million Vs. IBES Estimate USD 113 Million
Reuters · 05/04 20:05
More
Webull provides a variety of real-time WGSWW stock news. You can receive the latest news about GeneDx Holdings Corp through multiple platforms. This information may help you make smarter investment decisions.
About WGSWW
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.